[go: up one dir, main page]

GB0218921D0 - Novel vaccine - Google Patents

Novel vaccine

Info

Publication number
GB0218921D0
GB0218921D0 GBGB0218921.5A GB0218921A GB0218921D0 GB 0218921 D0 GB0218921 D0 GB 0218921D0 GB 0218921 A GB0218921 A GB 0218921A GB 0218921 D0 GB0218921 D0 GB 0218921D0
Authority
GB
United Kingdom
Prior art keywords
novel vaccine
vaccine
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0218921.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB0218921.5A priority Critical patent/GB0218921D0/en
Publication of GB0218921D0 publication Critical patent/GB0218921D0/en
Priority to AU2003260414A priority patent/AU2003260414A1/en
Priority to PCT/EP2003/009011 priority patent/WO2004016281A1/en
Ceased legal-status Critical Current

Links

GBGB0218921.5A 2002-08-14 2002-08-14 Novel vaccine Ceased GB0218921D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0218921.5A GB0218921D0 (en) 2002-08-14 2002-08-14 Novel vaccine
AU2003260414A AU2003260414A1 (en) 2002-08-14 2003-08-12 Intradermal influenza vaccine compositions containing an adp-ribosylating factor
PCT/EP2003/009011 WO2004016281A1 (en) 2002-08-14 2003-08-12 Intradermal influenza vaccine compositions containing an adp-ribosylating factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0218921.5A GB0218921D0 (en) 2002-08-14 2002-08-14 Novel vaccine

Publications (1)

Publication Number Publication Date
GB0218921D0 true GB0218921D0 (en) 2002-09-25

Family

ID=9942319

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0218921.5A Ceased GB0218921D0 (en) 2002-08-14 2002-08-14 Novel vaccine

Country Status (3)

Country Link
AU (1) AU2003260414A1 (en)
GB (1) GB0218921D0 (en)
WO (1) WO2004016281A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
WO2005117958A1 (en) * 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
US20070292386A9 (en) * 2004-12-02 2007-12-20 Campbell Robert L Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
HRP20120825T1 (en) * 2007-06-14 2012-11-30 Crucell Switzerland Ag Intradermal influenza vaccine
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP2275133A1 (en) * 1999-02-26 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Use of bioadhesives and adjuvants for the mucosal delivery of antigens
AU784781B2 (en) * 1999-11-10 2006-06-15 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
JP2004529906A (en) * 2001-03-19 2004-09-30 イオマイ コーポレイシヨン Percutaneous immunostimulation

Also Published As

Publication number Publication date
WO2004016281A1 (en) 2004-02-26
AU2003260414A1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
GB0213622D0 (en) Vaccine Corporation
GB0226722D0 (en) Vaccine
GB0202901D0 (en) Novel vaccine
GB0225788D0 (en) Vaccine
GB0225786D0 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0228715D0 (en) Vaccine
GB0218921D0 (en) Novel vaccine
GB0209878D0 (en) Vaccine
PL376534A1 (en) Vaccine
AU2003237701A8 (en) Vaccines
GB0206595D0 (en) Vaccine
IL156434A0 (en) Vaccine
GB0226179D0 (en) Vaccine
GB0223355D0 (en) Vaccine
GB0218037D0 (en) Vaccine composition
GB0216582D0 (en) Vaccine
GB0228716D0 (en) Vaccine
GB0218036D0 (en) Vaccine
GB0220211D0 (en) Vaccine
GB0213364D0 (en) Vaccine
GB0227619D0 (en) Vaccine
GB0209724D0 (en) Vaccine
GB0220212D0 (en) Vaccine
GB0206575D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)